Introduction
Bezafibrate, a second-generation fibrate drug, is used clinically as a hypolipidemic agent. Bezafibrate treatment lowers serum triglyceride and cholesterol levels by more than 25% and 10%, respectively, in patients with hyperlipidemia [1] [2] [3] [4] , and the Bezafibrate Infarction Prevention study has demonstrated a relationship between the lipid-lowering effects of bezafibrate and a reduction of the risk of cardiovascular events in dyslipidemic patients with coronary artery disease [5] . The molecular mechanism underlying the triglyceride-reducing effect of bezafibrate is due in part to the induction of lipoprotein lipase activity mediated by the activation of peroxisome proliferator-activated receptor α (PPARα), a member of the nuclear receptor superfamily [6, 7] . However, the molecular mechanism underlying its effect on cholesterol metabolism has not yet been fully elucidated.
PPARα is highly expressed in the liver, kidney, and heart, and functions as a critical regulator of fatty acid metabolism [8] [9] [10] [11] . Recently, several studies using a Ppara-null mouse model established a possible direct involvement of PPARα in the regulation of cholesterol metabolism. For example, PPARα activation enhances hepatic expression of mRNA encoding sterol 12α-hydroxylase (CYP8B1), an enzyme involved in bile acid synthesis from cholesterol [12] , and multidrug resistance 2 (Mdr2), a phospholipid transporter for bile formation [13] . On the other hand, it is known that bezafibrate can also activate other PPAR subtypes [β (δ) and γ] [14] [15] [16] . Thus, it remains unclear whether the effect of bezafibrate on cholesterol reduction is singularly due to its effect on PPARα.
In the present study, the contribution of PPARα to the cholesterol-reducing effect 5 of bezafibrate was examined using Ppara-null mice. With respect to this issue, there is a marked discrepancy between bezafibrate dosages used in previous rodent studies and those typically administered in the clinic; although the appropriate dosage for humans is estimated to be less than or equal to 10 mg/kg/day, studies in rodent models have often opted for high-dose regimens (50 mg/kg/day or more) [16] [17] [18] [19] . In the present study, therefore, wild-type and Ppara-null mice were treated with bezafibrate at high (100 mg/kg/day) or low (10 mg/kg/day) doses. Unexpectedly, low-dose bezafibrate treatment reduced serum and hepatic cholesterol concentrations in the absence of prominent PPAR activation.
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Materials and methods
Materials
Bezafibrate (2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropionic acid) was kindly provided by Kissei Pharmaceutical Co., Ltd. (Matsumoto, Japan).
Carboxymethylcellulose, Cholesterol E-Test kit, Free Cholesterol E-Test kit, Triglyceride E-Test kit, and Triton X-100 were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), and 3, 3'-diaminobenzidine (DAB) tetrahydrochloride was from Dojindo Laboratories (Kumamoto, Japan). RNeasy Mini Kit was obtained from QIAGEN (Hilden, Germany). Reverse transcript reagents were purchased from Invitrogen Corporation (Carlsbad, CA, USA). Power SYBR Green PCR Master Mix was obtained from Applied Biosystems (Foster City, CA, USA). BCA Protein Assay Kit and 1-Step NBT/BCIP reagent were purchased from Pierce Biotechnology (Rockford, IL, USA). Nitrocellulose membrane was obtained from GE Healthcare (Chalfont St.
Giles, UK). Rabbit polyclonal antibodies against 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), cholesterol 7α-hydroxylase (CYP7A1), sterol regulatory element-binding protein 2 (SREBP2), fatty acid translocase (CD36), actin, and histone H1, as well as goat polyclonal antibodies against squalene synthase (SQS), oxysterol 7α-hydroxylase (CYP7B1), acetyl-CoA carboxylase 2 (ACC2), pyruvate dehydrogenase kinase 4 (PDK4), and adipocyte fatty acid-binding protein (aP2) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal antibodies against acyl-CoA oxidase (AOX) and cytosolic thioesterase (CTE) were described elsewhere [20, 21] . Alkaline phosphatase-conjugated goat anti-rabbit IgG and rabbit anti-goat IgG antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). 
Animals and bezafibrate treatment
Ppara-null mice on a Sv/129 genetic background were described elsewhere [22] .
Twelve-week-old male Sv/129 wild-type and Ppara-null mice (25-30 g body weight)
were assigned to one of three groups (control group, low-dose bezafibrate group, or high-dose bezafibrate group; n = 6 in each). The mice were housed in a temperatureand light-controlled environment (25 °C; 12 h light/dark cycle) and maintained with tap water ad libitum and a 7% fat-containing standard rodent diet. Bezafibrate was suspended in 1% (w/v) carboxymethylcellulose at final concentrations of 1.5 and 15 mg/mL for the 10 and 100 mg/kg/day treatments, respectively, and 0.2 mL of each suspension was administered by gavage once a day (10:00 a.m.) for 10 days. The same amount of 1% (w/v) carboxymethylcellulose without bezafibrate was administered in a similar manner to control mice. At the end of treatment, food was withdrawn from all mice overnight, mice were killed under anesthesia, and blood and livers were collected for analysis. All animal experiments were conducted in accordance with the animal care guidelines approved by the Shinshu University School of Medicine.
Measurement of lipids
Serum total cholesterol (TC) and triglyceride concentrations were measured using the Cholesterol E-Test Wako and Triglyceride E-Test Wako kits, respectively. Serum lipoprotein profiles were analyzed by high-performance liquid chromatography with an on-line dual detection system (Skylight Biotech., Akita, Japan) [23] . To measure hepatic cholesterol content, total lipid in liver tissue (50 mg) was extracted according to the hexane/isopropanol method [24] . The lipid extract was solubilized in distilled water by the addition of Triton X-100 as described previously with minor modifications [25] , and cholesterol was then measured. Measurement of liver free cholesterol content was carried out using the Free Cholesterol E-Test Wako kit. Liver cholesteryl ester levels were calculated as the difference between liver TC and free cholesterol levels.
Analysis of mRNA expression
Total liver RNA was extracted using the RNeasy Mini Kit, and mRNA was reverse-transcribed using oligo-dT priming. Levels of mRNA were determined by quantitative real-time polymerase chain reaction (PCR) using SYBR Green chemistry on an ABI PRISM 7000 sequence detection system (Applied Biosystems). Specific primers were designed by Primer Express software (Applied Biosystems; Table 1 ). Each mRNA level was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, and then normalized to that of control wild-type mice.
Immunoblot analysis
Preparations of whole liver lysate and hepatic nuclear fraction were performed as described previously [26] [27] [28] . Protein concentrations were determined using the BCA Protein Assay Kit. Whole liver lysates or nuclear fractions (50 μg protein) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After blocking, these membranes were incubated with primary antibodies followed by alkaline phosphatase-conjugated secondary antibodies, and then treated with 1-Step NBT/BCIP substrate. The position of protein bands was determined by molecular weight. Band intensity was quantified densitometrically, normalized to that of actin or histone H1, and then normalized to that of control 9 wild-type mice.
Cytochemical staining and morphometric analysis of hepatic peroxisomes
Cytochemical staining of hepatic peroxisomes was carried out using the DAB technique as described elsewhere [28] . DAB-stained liver sections were visualized with both light and electron microscopy. Morphometric analysis of peroxisomes was also performed using electron micrographs at an original magnification of 4000×. 
Statistical analysis
Results are expressed as mean ± S.D. Statistical analysis was performed using SPSS software 11.5J for Windows (SPSS inc., Chicago, IL, USA). Comparison between the groups was made by means of Student's t test. A P < 0.05 was considered to be statistically significant.
Results
Phenotype changes
All mice appeared to be healthy during the experimental period, and no significant differences in food consumption or body weight were observed. Liver/body weight ratio was increased only in wild-type mice that received high-dose bezafibrate (Fig. 1A ).
Serum TC concentrations were slightly increased by high-dose bezafibrate treatment in wild-type, but not in Ppara-null mice, and were decreased by low-dose bezafibrate in both genotypes ( was decreased in wild-type mice only (14.7 ± 3.2 vs. 25.9 ± 4.8%, P = 0.008). These two parameters were also reduced in wild-type mice that received high-dose bezafibrate (data not shown). These findings indicate that the cholesterol-lowering effect of bezafibrate occurs in a PPARα-independent manner in cases of low-dose administration.
Effects on cholesterol biosynthesis
To elucidate the molecular mechanism of the effects of bezafibrate, hepatic expression of mRNA encoding cholesterol biosynthetic enzymes was first measured.
High-dose bezafibrate treatment markedly increased the expression of 3-hydroxy-3-methylglutaryl-CoA synthase (HMGS), HMGR, farnesyl pyrophosphate synthase (FPPS), and SQS mRNA in wild-type mice only ( Fig. 2A) , suggesting that these changes may be mediated by PPARα. In contrast, low-dose bezafibrate treatment significantly decreased the expression of HMGS, HMGR, FPPS, and SQS mRNA in both genotypes ( Fig. 2A) . Immunoblot analysis revealed that changes in HMGR and SQS protein expression were consistent with those in mRNA levels ( Fig. 2B and C ).
These results demonstrate that de novo cholesterogenesis pathway is markedly suppressed specifically by low-dose bezafibrate treatment in both genotypes.
Effects on cholesterol catabolism
To determine whether bezafibrate treatment affected cholesterol catabolism, the expression of mRNA encoding bile acid synthetic enzymes was examined. High-dose bezafibrate treatment markedly increased the expression of CYP7A1, CYP8B1, and branched-chain AOX (AOX2) in wild-type mice, while their Ppara-null counterparts exhibited an increase in CYP7A1 expression, but a decrease in CYP8B1 (Fig. 3A) . On the other hand, low-dose treatment significantly enhanced the expression of CYP7A1
and CYP7B1 mRNA in both genotypes (Fig. 3A) . These increases were confirmed by immunoblot analysis (Fig. 3B and C) . Bezafibrate treatment did not affect the expression of mRNA encoding sterol 27-hydroxylase (CYP27A1), 3β-hydroxysteroid dehydrogenase (3β-HSD), or cholesterol 25-hydroxylase (Ch25h). These results suggest that increased expression of two cholesterol-catabolizing enzymes (i.e., CYP7A1 and CYP7B1) may at least partially contribute to the cholesterol-reducing effect observed in wild-type and Ppara-null mice administered with low-dose bezafibrate.
Effects on cholesterol influx, efflux, and intracellular sterol transport
Next, the expression of mRNA encoding proteins involved in cholesterol influx and efflux was investigated. In wild-type mice, high-dose bezafibrate treatment markedly enhanced the expression of apolipoprotein A2 (apoA2), apoE, ATP-binding cassette (ABC) transporter A1 (ABCA1), scavenger receptor B1 (SR-B1), and low-density lipoprotein receptor (LDLR) mRNA, while low-dose treatment increased that of ABCA1 ( Fig. 4A and B) . These changes were not observed in similarly treated
Ppara-null mice.
The expression of mRNA encoding sterol transporters and acyltransferases was also evaluated to determine the effect of bezafibrate on the intracellular mobility of cholesterol and its metabolites. High-dose bezafibrate treatment significantly elevated mRNA levels of Niemann-Pick type C1 protein (NPC1), sterol carrier protein 2 (SCP2), liver fatty acid-binding protein (L-FABP), and acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in wild-type mice ( Fig. 4C and D) . Ppara-null mice that received high-dose bezafibrate showed an increase in L-FABP mRNA expression. Low-dose bezafibrate treatment also elevated mRNA levels of NPC1 and L-FABP in wild-type mice, but not in Ppara-null mice ( Fig. 4C and D) . Bile acid-CoA:amino acid N-acyltransferase (BAAT) mRNA expression was unchanged.
Effects on bile secretion and bile acid reabsorption
High-dose bezafibrate treatment markedly increased mRNA expression of transporters related to bile secretion, including Mdr1, Mdr2, multidrug resistance-associated protein 2 (Mrp2), Mrp3, ABCG5, and ABCG8 in wild-type mice (Fig. 5A) . No such effects from low-dose treatment were noted. Expression of bile salt export pump (BSEP) mRNA was constant.
Next, the expression of mRNA encoding bile salt transporters was examined since approximately 95% of bile salts are reabsorbed in the liver through enterohepatic circulation [29] . High-dose bezafibrate treatment significantly enhanced sodium-taurocholate cotransporting polypeptide (NTCP) mRNA expression in both genotypes, while low-dose treatment did not (Fig. 5B) . Levels of organic anion transporting polypeptide 1 (OATP1) and OATP2 mRNA were unchanged by the treatment.
Alterations in transcription factor expression
In order to investigate changes in transcription factors, the expression of mRNA encoding PPARs and other factors related to cholesterol metabolism was evaluated.
High-dose bezafibrate treatment markedly elevated mRNA levels of PPARα, liver X receptor α (LXRα), farnesoid X receptor (FXR), and SREBP2 in wild-type mice only (Fig. 6A) . Interestingly, the low-dose treatment significantly down-regulated SREBP2 mRNA levels in both genotypes (Fig. 6A) . PPARβ mRNA was considerably decreased by bezafibrate in both genotypes at both dosages, while PPARγ mRNA remained unchanged. Immunoblot analysis showed that the changes in nuclear SREBP2 levels were in accordance with those at the transcriptional levels ( Fig. 6B and C) . Additionally, nuclear SREBP2 levels were correlated with the expression of its target genes, such as 14 HMGS, HMGR, FPPS, and SQS (Fig. 2) .
Effects on PPAR target gene expression and peroxisome proliferation
As described above, several PPARα-independent effects were found in the low-dose bezafibrate treatment group, leading to the hypothesis that low doses of bezafibrate function via mechanisms other than PPARα activation. To address this issue, the expression of representative PPARα target genes, including AOX and CTE [30] , was investigated in wild-type mice. As expected, high-dose bezafibrate treatment markedly elevated expression of these genes, but low-dose treatment did not ( Fig. 7A-C). These findings were in agreement with the result that PPARα mRNA was not elevated by low-dose administration (Fig. 6A) since PPARα activation is known to activate its own transcription [11, 31] . Additionally, peroxisome proliferation, a well-known indicator of PPARα activation [22] , was not observed in the low-dose group ( Fig. 7D and E) . Furthermore, to determine the contribution of low-dose bezafibrate on PPARβ and/or PPARγ activation, the expression of target genes of PPARβ (ACC2 [32] and PDK4 [33] ), PPARα/γ (CD36 [34] ), and PPARγ (aP2 [35] )
were analyzed in both genotypes, but showed no increase in mice treated with low-dose bezafibrate (Fig. 8) . Overall, these results strongly suggest that low doses of bezafibrate do not induce significant activation of murine PPARs.
Discussion
The present study provides novel and unexpected evidence that the pharmacological action of bezafibrate on cholesterol metabolism varies considerably according to its dosage. Treatment with high-dose bezafibrate (100 mg/kg/day), a dosage similar to that used in previous rodent experiments, resulted in both a slight increase in serum TC concentration and a marked decrease in hepatic TC in a PPARα-dependent manner, accompanied with strong PPAR activation. In contrast, treatment with low-dose bezafibrate (10 mg/kg/day), corresponding approximately to the dosage used in human clinical practice, decreased serum and hepatic cholesterol concentrations in the absence of significant PPAR activation. As far as we know, this is the first study that explores the dose-dependent effects of bezafibrate in mice.
High-dose bezafibrate treatment caused several conflicting changes in the mRNA levels of various enzymes, transporters, and receptors related to hepatic cholesterol metabolism in a PPARα-dependent fashion. Specifically, mRNA levels of proteins involved in cholesterol biosynthesis (HMGS, HMGR, FPPS, and SQS), catabolism (CYP7A1, CYP8B1, and AOX2), uptake (SR-B1 and LDLR), and excretion (apoA2, apoE, ABCA1, and ABCG5/8) were all elevated. Although this simultaneous induction was too complicated to interpret all of the molecular mechanisms involved, these responses were likely associated with the both direct and indirect effects of intensive PPAR activation. It is conceivable that the elevated levels of LXRα, FXR, and SREBP2
found following high-dose bezafibrate treatment affected the expression of numerous proteins involved in cholesterol/bile acid metabolism; all three have been shown to regulate expression of CYP7A1 and ABC transporters [36, 37] , apoE, Mdr2, and Mrp2 [38] [39] [40] , and cholesterogenic enzymes and LDLR [41, 42] . Moreover, hepatic expression of the xenobiotic transporter Mdr1 was up-regulated by high-dose treatment in a PPARα-dependent manner, suggesting the possible influence of PPARα activation-induced stress, such as rodent-specific hepatomegaly [13] . Therefore, previous results in rodents treated with high-dose bezafibrate may not accurately reflect the pharmacological effect of this drug in humans.
The molecular mechanism of the cholesterol-reducing effect of low-dose bezafibrate seemed to be due to suppression of SREBP2-regulated de novo cholesterogenesis and stimulation of cholesterol catabolism through increased expression of two 7α-hydroxylases, CYP7A1 and CYP7B1. A previous study suggested that the expression of human CYP7B1 is suppressed by SREBPs [43] . In the present study, CYP7B1 expression in both genotypes under low-dose bezafibrate treatment reacted inversely to SREBP2; therefore, increases in CYP7B1 expression might be accompanied by attenuation of SREBP2. In contrast to CYP7B1, CYP7A1 expression was up-regulated by bezafibrate treatment in a PPARα-independent, dose-dependent manner. Thus, these changes might be attributable to some as yet unknown bezafibrate-specific action. The down-regulation of SREBP2 by low-dose treatment occurred at the transcriptional level. Transcription of SREBP2 is known to be regulated by mature SREBP2 translocated to the nucleus through a proteolytic processing step controlled by several proteins, including SREBP cleavage-activating protein and site-1 protease [41, 42, 44, 45] . Bezafibrate might influence the proteolysis of SREBP2
through modulation of such factors, though further experiments are needed in this regard.
The present study revealed that low-dose bezafibrate treatment increased the expression of ABCA1, NPC1, and L-FABP in the presence of PPARα. Previous reports have established a prominent role for hepatic ABCA1 in the regulation of plasma high-density lipoprotein cholesterol levels [46, 47] . In addition, NPC1 has been shown to transport free cholesterol from lysosomes to the plasma membrane, contributing to cholesterol efflux through the ABCA1 pathway [48] . Therefore, these changes may be partly related to bezafibrate enhancement of high-density lipoprotein cholesterol in humans. L-FABP is known as a major bile acid transporter [49, 50] , and the enhancement of its expression may be implicated in facilitation of intracellular bile acid mobility. Recently, the efficacy of bezafibrate has been demonstrated in patients with chronic cholestatic liver diseases, such as primary biliary cirrhosis [51] [52] [53] . The present results concerning L-FABP induction might partially explain the beneficial effects of bezafibrate against such diseases. Taken together, our results suggest the importance of PPARα on understanding the pharmacological effects of bezafibrate.
The above-mentioned dose discrepancy between rodents and humans could be due to pharmacokinetic differences; dose justification alone might be inadequate to compare the conditions. However, our preliminary analysis and the previous reports have demonstrated that maximum plasma concentrations (Cmax) and area under the concentration-time curve (AUC) values in rats after the single high-dose administration of bezafibrate were quite different from those in healthy volunteers after the single intake at the clinical dose (mean Cmax, 140 vs. 11 μg/mL; mean AUC values, 1520 vs.
39 μg·h/mL) [54, 55] . On the other hand, these parameters in rats after the single low-dose administration were relatively similar to those in healthy volunteers (21 μg/mL and 107 μg·h/mL, respectively). Therefore, the phenomena observed in mice under low-dose administration might reflect the conditions in bezafibrate-treated humans more accurately than those in mice with high-dose administration.
This study showed that low-dose bezafibrate treatment reduced circulating cholesterol and altered hepatic cholesterol metabolism through a PPARα-independent mechanism in mice. Although no significant activation of any PPAR subtype was determined under low-dose treatment as estimated by the expression of various PPAR target genes and morphometry of hepatic peroxisomes, we cannot rule out the possibility that the PPARα-independent effect was nonetheless somehow mediated by PPARβ, PPARγ, or both. Further studies using mice lacking all PPAR subtypes are needed to address this issue. Additionally, cholesterol-metabolizing pathways in mice partly differ from those in humans. For example, the degree of contribution of the alternative pathway to overall bile acid synthesis is thought to be low in mice compared to humans [36] . The same experiment using other mammals such as guinea pigs, which have more similarities in cholesterol metabolism to humans than mice [56, 57] , would confirm our results.
In conclusion, we demonstrated that the cholesterol-reducing effect of bezafibrate in mice at the clinically-relevant dose stems from suppression of cholesterol biosynthesis and enhancement of catabolism without significant PPAR activation.
Additionally, our results indicated remarkable differences in the mechanisms involved in bezafibrate action by comparing high-dose and low-dose treatments. These findings may lead to better identification of the mechanisms underlying the beneficial effects of bezafibrate in patients with dyslipidemia.
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Figure Legends high-dose (100 mg/kg/day) bezafibrate group. *P < 0.05, **P < 0.01, ***P < 0.001, between treated and untreated mice of the same genotype. (n = 6 in each group). Bars are identical to those in Fig. 2A . *P < 0.05, **P < 0.01, ***P < 0.001, between treated and untreated mice of the same genotype.
